Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab therapeutic drug monitoring-guided dose optimization in rheumatoid arthritis
NL-OMON20556Recruiting
- Sponsor
- Reade Rheumatology Research Institute
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (3 arms), sponsored by Reade Rheumatology Research Institute. Primary endpoint: Mean time-weighted DAS28-ESR at 28 weeks. Started Aug 2019; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON20556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20556.